维生素D预防慢阻肺急性加重:个体参与者数据系统综述与荟萃分析
本研究通过系统检索和个体参与者数据荟萃分析,纳入4项随机对照试验共560例慢阻肺患者,评估维生素D补充对中重度急性加重的影响。结果显示补充维生素D对总体加重率无显著影响,但基线25-羟维生素D<25 nmol/L者加重率显著降低,≥25 nmol/L者无获益,且未增加严重不良事件。
要点
- 维生素D补充未降低慢阻肺总体中重度急性加重率(aIRR 0.94)。
- 基线25-羟维生素D<25 nmol/L者补充后加重率显著降低(aIRR 0.55)。
- 基线25-羟维生素D≥25 nmol/L者无获益(aIRR 1.04),交互作用P=0.015。
核心结论
- 维生素D补充可安全且显著降低基线25-羟维生素D<25 nmol/L的慢阻肺患者中重度急性加重率。
- 基线25-羟维生素D≥25 nmol/L者补充维生素D未见保护作用。
研究设计与样本
- 纳入报告急性加重发生率的维生素D补充随机对照试验,共4项RCT、560例参与者。
- 对3项RCT中469/472(99.4%)参与者进行个体参与者数据荟萃分析,采用固定效应模型校正年龄、性别、GOLD气流受限分级和试验。
主要发现
- 补充维生素D未影响总体中重度慢阻肺急性加重率(aIRR 0.94,95%CI 0.78–1.13)。
- 基线25-羟维生素D<25 nmol/L者中,补充维生素D显著降低中重度急性加重率(aIRR 0.55,95%CI 0.36–0.84)。
- 基线25-羟维生素D≥25 nmol/L者中无保护效应(aIRR 1.04,95%CI 0.85–1.27;交互作用P=0.015)。
- 维生素D未影响至少发生一次严重不良事件的参与者比例(校正OR 1.16,95%CI 0.76–1.75)。
关键数值与推荐
- 基线25-羟维生素D<25 nmol/L者中重度急性加重aIRR 0.55(95%CI 0.36–0.84)。
- 基线25-羟维生素D≥25 nmol/L者中重度急性加重aIRR 1.04(95%CI 0.85–1.27),交互作用P=0.015。
- 总体中重度急性加重aIRR 0.94(95%CI 0.78–1.13)。
- 至少一次严重不良事件校正OR 1.16(95%CI 0.76–1.75)。
临床怎么用
- 对慢阻肺患者可检测基线25-羟维生素D水平,识别<25 nmol/L者可能从维生素D补充中获益。
- 基线25-羟维生素D≥25 nmol/L的慢阻肺患者不建议仅以预防急性加重为目的补充维生素D。
局限性
- 仅4项RCT符合纳入标准,个体参与者数据仅来自3项RCT。
- 总样本量有限(560例),亚组分析基于预设但样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised controlled trials (RCTs) of vitamin D to prevent COPD exacerbations have yielded conflicting results.Individual participant data meta-analysis could identify factors that explain this variation. METHODS: PubMed, Embase, the Cochrane Central Register of Controlled Trials and Web of Science were searched from inception up to and including 5 October 2017 to identify RCTs of vitamin D supplementation in patients with COPD that reported incidence of acute exacerbations. Individual participant data meta-analysis was performed using fixed effects models adjusting for age, sex, Global Initiative for Chronic Obstructive Lung Disease spirometric grade and trial. RESULTS: Four eligible RCTs (total 560 participants) were identified; individual participant data were obtained for 469/472 (99.4%) participants in three RCTs. Supplementation did not influence overall rate of moderate/severe COPD exacerbations (adjusted incidence rate ratio (aIRR) 0.94, 95% CI 0.78 to 1.13). Prespecified subgroup analysis revealed that protective effects were seen in participants with baseline 25-hydroxyvitamin D levels <25 nmol/L (aIRR 0.55, 95% CI 0.36 to 0.84) but not in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (aIRR 1.04, 95% CI 0.85 to 1.27; p for interaction=0.015). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted OR 1.16, 95% CI 0.76 to 1.75). CONCLUSIONS: Vitamin D supplementation safely and substantially reduced the rate of moderate/severe COPD exacerbations in patients with baseline 25-hydroxyvitamin D levels <25 nmol/L but not in those with higher levels. TRIAL REGISTRATION NUMBER: CRD42014013953.
引用
- Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. 2019. PMID: 30630893. doi:10.1136/thoraxjnl-2018-212092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。